Database : MEDLINE
Search on : uterine and cervical and dysplasia [Words]
References found : 5382 [refine]
Displaying: 1 .. 10   in format [Detailed]

page 1 of 539 go to page                         

  1 / 5382 MEDLINE  
              next record last record
select
to print
Photocopy
Full text

[PMID]: 29516923
[Au] Autor:Das L; Naskar S; Sarkar T; Maiti AK; Das S; Chatterjee J
[Ad] Address:Department of Medical Science and Technology, Indian Institute of Technology, Kharagpur; Department of Materials Engineering, Indian Institute of Science, Bangalore, Karnataka, India.
[Ti] Title:Immunohistochemical evaluation of prime molecules in cervical lesions towards assessment of malignant potentiality.
[So] Source:J Cancer Res Ther;14(2):377-381, 2018 Jan-Mar.
[Is] ISSN:1998-4138
[Cp] Country of publication:India
[La] Language:eng
[Ab] Abstract:Objective: A comparative immunohistochemical evaluation of p63, CD105, and E-cadherin expression pattern in histopathologically confirmed normal cervical epithelium (NCM), dysplastic cervical epithelium (DYS) and squamous cell carcinoma (SCC) of uterine cervix towards assessing malignant potentiality of the precancerous condition. Materials and Methods: The biopsies from cervical mucosa (normal, dysplasia, and cancer) were studied by routine hematoxylin and eosin (H and E) and by immunohistochemistry for p63, E-cadherin, and CD105 expression. The expressions of these molecules were assessed in a semiquantitative way by (i) counting p63 cell population and distribution, (ii) intensity scoring of E-cadherin along the expression path, and (iii) measuring CD105 expression density. Result: p63 cells were highest in carcinomas followed by dysplasia and normal. An abrupt increase in CD105 expression was observed through change of normal to dysplasia and cancer. A decrease in membranous E-cadherin expression was noticed in the transformation from normal to precancer and cancers. Conclusion: The malignant potential of the dysplastic conditions is likely to be correlated with upregulation in p63 and CD105 expression and a simultaneous downregulation of membranous E-cadherin.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180308
[Lr] Last revision date:180308
[St] Status:In-Process
[do] DOI:10.4103/0973-1482.158029

  2 / 5382 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29415121
[Au] Autor:Nguyen BT; Dengler KL; Saunders RD
[Ad] Address:Department of Obstetrics and Gynecology, San Antonio Military Medical Center 3551 Roger Brooke Drive, Fort Sam Houston, San Antonio, TX 78234.
[Ti] Title:Mayer-Rokitansky-Kuster-Hauser Syndrome: A Unique Case Presentation.
[So] Source:Mil Med;, 2018 Feb 05.
[Is] ISSN:1930-613X
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:Background: Mayer-Rokitansky-Kuster-Hauser (MRKH) syndrome is a congenital condition characterized by aplasia of the vagina with or without concurrent uterine and/or cervical aplasia. Type II (MURCS) is a rare form involving MUllerian agenesis, Renal agenesis, and Cervicothoracic Somite anomalies. Case: A 17-yr-old virginal female presented for evaluation of primary amenorrhea and pelvic pain. Her medical history was significant for a bicuspid aortic valve and right radial dysplasia. She demonstrated normal secondary sexual development and a normal karyotype. Pelvic magnetic resonance imaging revealed an aplastic vaginal, no identifiable cervix or uterus, and normal ovaries. A laparoscopy was performed for the evaluation of pain and findings were significant for bilateral uterine horn and fallopian tube remnants noted along the pelvic sidewalls. This patient evaluation suggests a unique presentation of MURCS association. Conclusion: To our knowledge, this is the first case of MRKH presenting with a bicuspid aortic valve and radial dysplasia. A review of the literature reveals no other cases of MRKH with these unique anomalies.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180308
[Lr] Last revision date:180308
[St] Status:Publisher
[do] DOI:10.1093/milmed/usx066

  3 / 5382 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29504143
[Au] Autor:Perminov E; Mangosing S; Confer A; Gonzalez O; Crawford JR; Schlabritz-Loutsevitch N; Kumar S; Dick E
[Ad] Address:Southwest National Primate Research Center, Texas Biomedical Research Institute, San Antonio, TX, USA.
[Ti] Title:A case report of ovotesticular disorder of sex development (OT-DSD) in a baboon (Papio spp.) and a brief review of the non-human primate literature.
[So] Source:J Med Primatol;, 2018 Mar 05.
[Is] ISSN:1600-0684
[Cp] Country of publication:Denmark
[La] Language:eng
[Ab] Abstract:Disorders of sexual development are rare in non-human primates. We report a case of true hermaphroditism in a 19-year-old, nulliparous, female baboon (Papio spp.). At necropsy, the animal was obese with adequate muscle mass and hydration. Reproductive organs appeared normal with the exception of 2 firm nodular structures in the myometrium (1-1.5 cm diameter) and a thickened, dark endocervical mucosa. Histologically, both gonads were ovotestes and contained discrete areas of ovarian and testicular tissue. There were follicles in various stages of development surrounded by ovarian stroma. Other areas contained hypoplastic seminiferous tubules lined by Sertoli cells, but lacked germ cells and spermatozoa. The uterine lesions were consistent with adenomyosis and cystic endometrial hyperplasia. Cervical lesions were consistent with atypical glandular hyperplasia and squamous metaplasia with dysplasia. We report the first case of ovotesticular disorder of sexual development (OT-DSD), or true hermaphroditism in a baboon.
[Pt] Publication type:JOURNAL ARTICLE; REVIEW
[Em] Entry month:1803
[Cu] Class update date: 180305
[Lr] Last revision date:180305
[St] Status:Publisher
[do] DOI:10.1111/jmp.12339

  4 / 5382 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29468549
[Au] Autor:Karpathiou G; Peoc'h M
[Ad] Address:Department of Pathology, University Hospital of St-Etienne, CEDEX2 St-Etienne, France. gakarpath@yahoo.gr.
[Ti] Title:Immunohistochemical Detection of p16 in Clinical Samples.
[So] Source:Methods Mol Biol;1726:123-142, 2018.
[Is] ISSN:1940-6029
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:P16 immunohistochemical expression, a surrogate marker of the retinoblastoma pathway, has become a major adjunct in the routine practice mostly of cervical and head/neck pathology, but with other indications too. In this chapter, a detailed immunohistochemical technique for the detection of p16 is described, followed by indications and interpretation of its expression in uterine, ovarian, vulvar, penile, head-and-neck, melanocytic, and other pathologies.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180222
[Lr] Last revision date:180222
[St] Status:In-Data-Review
[do] DOI:10.1007/978-1-4939-7565-5_12

  5 / 5382 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29298001
[Au] Autor:Ishchenko AI; Aleksandrov LS; Ishchenko AA; Hudoley EP
[Ti] Title:Method of Surgical Management of Genital Prolapse with Cervical Elongation.
[So] Source:Vestn Ross Akad Med Nauk;71(6):413-9, 2016.
[Is] ISSN:0869-6047
[Cp] Country of publication:Russia (Federation)
[La] Language:eng
[Ab] Abstract:Objectives: According to different authors, the percentage of genital prolapse among gynaecological diseases that require surgical correction reaches 28−38,9%. Pelvic muscle wasting is a special kind of pelvic prolapse, often leading to cervical elongation and hypertrophy. Contemporary methods of treatment for this condition have the high rate of relapse­ 8,9−22%, thus urging to improve the existing techniques. Purpose: This research was to estimate the effectiveness of novel modification of Manchester operation in comparison with classic Manchester operation in the management of pelvic prolapse with cervical elongation. Methods: We enrolled 83 patients with pelvic prolapse and cervical elongation and divided them into two groups. In GroupI (n=47) we used the novel surgical method, supplementing original Manchester procedure with cervical stump fixation and other improvements. In GroupII we used original Manchester procedure. We compared laboratory measures as well as surgery duration, blood loss, incidence of complications, and duration of post-operational hospital stay. Patients were followed-up for 2years to estimate long-term effectiveness of surgical intervention. Statistical analysis was performed in SPSS 17.0. Results: Surgery duration in GroupII was significantly longer (47,8±26,2 vs 57,5±35,1 minutes, p<0.05). There were no significant differences in lab tests, post-operational hospital stay (5,2±0,9 vs 7,3±1,2) and incidence of post-operational complications (3 vs 4 cases). Over the 2 years of follow-up we registered 1 case of relapse in Group I and 3 cases of relapse in Group II, thus estimating the effectiveness of surgery as 97,9 vs 91,7%, a non-significant difference. We noticed that all relapsed women had signs of systemic dysplasia of connective tissue. Conclusion: Suggested modification of Manchester operation improves duration of surgical intervention itself, while providing a comparable level of effectiveness.
[Mh] MeSH terms primary: Gynecologic Surgical Procedures
Postoperative Complications
Uterine Prolapse
[Mh] MeSH terms secundary: Aged
Female
Gynecologic Surgical Procedures/adverse effects
Gynecologic Surgical Procedures/methods
Humans
Long Term Adverse Effects/diagnosis
Long Term Adverse Effects/etiology
Middle Aged
Operative Time
Postoperative Complications/diagnosis
Postoperative Complications/etiology
Recurrence
Treatment Outcome
Uterine Prolapse/diagnosis
Uterine Prolapse/surgery
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180220
[Lr] Last revision date:180220
[Js] Journal subset:IM
[Da] Date of entry for processing:180104
[St] Status:MEDLINE
[do] DOI:10.15690/vramn727

  6 / 5382 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29179269
[Au] Autor:Huang AJ; Zhao Y; Zou XL; Yan J; Zhao C; Cui SH; Li YY; Ren LH; Li JR; Li MZ; Wang Y; Wang JL; Wei LH
[Ad] Address:Department of Obstetrics and Gynecology, Peking University People's Hospital, Beijing 100044, China.
[Ti] Title:[Study on clinical management of HPV(+)/Pap(-) during cervical cancer screening].
[So] Source:Zhonghua Fu Chan Ke Za Zhi;52(11):745-750, 2017 Nov 25.
[Is] ISSN:0529-567X
[Cp] Country of publication:China
[La] Language:chi
[Ab] Abstract:To study the clinical management way for HPV(+)/papanicolaou (Pap)(-) during cervical cancer screening. To analyze retrospectively the data from the patients who had loop electrical excision procedure (LEEP) for biopsy confirmed cervical intraepithelial neoplasia (CIN) â…¡ in Peking University People's Hospital from Jan. 2010 to Dec. 2014. (1) For biopsy confirmed CIN â…¡, HPV positive rate was 98.5% (135/137), Pap test positive [≥atypical squamous cell of undetermined significance (ASCUS)] rate was 69.3% (95/137), there was significant difference between them (χ(2)=43.32, 0.01). (2) For the 42 patients with HPV(+)/Pap(-), whose cytology slides were reviewed again. Among them, the interpretations of there were 16 cases confirmed as the same before, while 26 cases were changed to abnormal (≥ASCUS). Cytology be misdiagnosed was 19.0% (26/137) at the first review. Among the 26 cases, 13 (50.0%) cases were missed for the little amount of abnormal cells, 8 (30.8%) cases for mild atypical morphology changed; the other 5 (19.2%) cases missed for stain problems. (3) For the cervical LEEP samples, 37 cases of the pathology diagnosis were upgrade to CIN â…¢(+), among them, 2 cases of microinvasive cervical carcinoma, 1 case of invasive cancer, 34 cases of CIN â…¢; 37 cases were CINâ…  or no lesion found; 63 cases were still CIN â…¡. Four to six months later after LEEP, the cytology abnormal rate was 11.7% (16/137), and the HR-HPV positive rate was 34.3% (47/137). Compared with cytology alone, cytology combined with HPV testing increase the sensitivity of cervical high grade lesion. For the cases of HPV(+)/Pap(-) cases, the cytology slides should be reviewed. The quality control of cervical exfoliate sample collection and interpretation should be strengthened. LEEP procedure is not only a treatment method, but also it could provide samples to confirm the diagnosis.
[Mh] MeSH terms primary: Cervical Intraepithelial Neoplasia/pathology
Papanicolaou Test
Papillomaviridae/isolation & purification
Uterine Cervical Neoplasms/pathology
Vaginal Smears
[Mh] MeSH terms secundary: Adult
Cervical Intraepithelial Neoplasia/virology
Early Detection of Cancer
Female
Humans
Middle Aged
Papillomavirus Infections/diagnosis
Retrospective Studies
Sensitivity and Specificity
Specimen Handling
Uterine Cervical Dysplasia
Uterine Cervical Neoplasms/virology
Vaginal Smears/methods
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1801
[Cu] Class update date: 180111
[Lr] Last revision date:180111
[Js] Journal subset:IM
[Da] Date of entry for processing:171128
[St] Status:MEDLINE
[do] DOI:10.3760/cma.j.issn.0529-567X.2017.11.006

  7 / 5382 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29215531
[Au] Autor:Silverberg MJ; Leyden WA; Chi A; Gregorich S; Huchko MJ; Kulasingam S; Kuppermann M; Seto A; Smith-McCune KK; Sawaya GF
[Ad] Address:Division of Research, Kaiser Permanente, Oakland, California; the Department of Epidemiology and Biostatistics, the School of Pharmacy, the Department of Medicine, and the Department of Obstetrics, Gynecology and Reproductive Sciences, University of California, San Francisco, San Francisco, California; the Department of Obstetrics and Gynecology and the Global Health Institute, Duke University, Durham, North Carolina; and the Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, Minnesota.
[Ti] Title:Human Immunodeficiency Virus (HIV)- and Non-HIV-Associated Immunosuppression and Risk of Cervical Neoplasia.
[So] Source:Obstet Gynecol;131(1):47-55, 2018 Jan.
[Is] ISSN:1873-233X
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:OBJECTIVE: To estimate the risk of cervical intraepithelial neoplasia grade 2, 2-3, 3, adenocarcinoma in situ, or cancer (CIN 2 or worse) among women with human immunodeficiency virus (HIV)- and non-HIV-associated immunosuppression. METHODS: We performed a case-control study of 20,146 women with incident CIN 2 or worse and 5:1 age-matched, incidence-density selected women in a control group (n=100,144) enrolled in an integrated health care system from 1996 to 2014. Adjusted rate ratios (RRs) from conditional logistic regression were obtained for HIV status (stratified by CD4 T-cells), solid organ transplant history, and immunosuppressive medication use. RESULTS: Risk of CIN 2 or worse was increased among women with HIV (n=36 women in the case group and 79 women in the control group; adjusted RR 2.0, 95% CI 1.3-3.0) compared with those without HIV and in solid organ transplant recipients (n=51 women in the case group and 68 women in the control group; RR 3.3, 95% CI 2.3-4.8) compared with women without a prior transplant. The highest risks were among women with HIV and less than 200 CD4 T-cells/microliter (n=9 women in the case group and eight women in the control group; RR 5.6, 95% CI 2.1-14.7) compared with those without HIV and in solid organ transplant recipients prescribed three or greater immunosuppressive medication classes (n=32 women in the case group and 33 women in the control group; RR 4.1, 95% CI 2.5-6.8) compared with women without a prior transplant and zero medication classes. No increased risks were observed for women with HIV and 500 or greater CD4 T-cells/microliter (n=9 women in the case group and 43 women in the control group; RR 0.8, 95% CI 0.4-1.7) compared with those without HIV or women without prior solid organ transplantation prescribed two or fewer immunosuppressive medication classes (n=1,262 women in the case group and 6,100 women in the control group; RR 0.95, 95% CI 0.89-1.01) compared with women without and a prior transplant and zero medication classes. CONCLUSION: Risk of CIN 2 or worse is increased in women with a prior solid organ transplant or who have HIV and CD4 cells/microliter less than 500 but not in women with HIV and higher CD4 levels or in women without a prior solid organ transplant but who are prescribed only one or two immunosuppressive medication classes.
[Mh] MeSH terms primary: Adenocarcinoma/virology
HIV Infections/immunology
Uterine Cervical Dysplasia/immunology
Uterine Cervical Dysplasia/virology
Uterine Cervical Neoplasms/immunology
Uterine Cervical Neoplasms/virology
[Mh] MeSH terms secundary: Adenocarcinoma/epidemiology
Adenocarcinoma/immunology
Adenocarcinoma/pathology
Adult
Age Distribution
California
Case-Control Studies
Female
HIV Infections/complications
Humans
Immunosuppression
Incidence
Logistic Models
Middle Aged
Neoplasm Invasiveness/pathology
Neoplasm Staging
Prognosis
Reference Values
Registries
Risk Assessment
Uterine Cervical Dysplasia/epidemiology
Uterine Cervical Dysplasia/pathology
Uterine Cervical Neoplasms/epidemiology
Uterine Cervical Neoplasms/pathology
[Pt] Publication type:COMPARATIVE STUDY; JOURNAL ARTICLE
[Em] Entry month:1801
[Cu] Class update date: 180108
[Lr] Last revision date:180108
[Js] Journal subset:AIM; IM
[Da] Date of entry for processing:171208
[St] Status:MEDLINE
[do] DOI:10.1097/AOG.0000000000002371

  8 / 5382 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29182627
[Au] Autor:Cocuzza CE; Martinelli M; Sina F; Piana A; Sotgiu G; Dell'Anna T; Musumeci R
[Ad] Address:Department of Medicine and Surgery (School of Medicine), University of Milano-Bicocca, Monza, Italy.
[Ti] Title:Human papillomavirus DNA detection in plasma and cervical samples of women with a recent history of low grade or precancerous cervical dysplasia.
[So] Source:PLoS One;12(11):e0188592, 2017.
[Is] ISSN:1932-6203
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Circulating HPV DNA has been previously described in women with advanced stages of cervical cancer and has been suggested to be a prognostic marker of disease recurrences and metastases. Only a few studies have reported the presence of HPV DNA in bloodstream of patients with low grade or precancerous cervical lesions. This study aimed to define if HPV DNA could be detected in plasma samples of 120 women referred for a recent history of cervical dysplasia who presented with lesions ranging from High Squamous Intraepithelial Lesion (H-SIL) to regressed normal cytology. HPV DNA detection was carried out in both plasma and cervical samples using type-specific real-time quantitative PCR assays identifying oncogenic HPV 16, 18, 31, 33, 45, 51 and 52. Overall, 34.2% (41/120) of plasma samples were shown to be positive for HPV DNA detection; HPV 45 (46.3%), HPV-51 (29.6%), and HPV 16 (18.5%) were the most frequently identified genotypes. The rate of HPV detection in paired cervical and plasma samples increased with advancing disease stage, ranging from 15.4% in women with regressed lesions to 38.9% in women with HSIL; HPV 16 resulted the most common genotype identified in women found to be HPV DNA positive in both cervical and plasma samples. Moreover, HPV 16 showed the highest median viral load value in both cervical and plasma samples, with 48,313 copies/104 cells and 1,099 copies/ml, respectively. Results obtained in this study confirm that HPV DNA can be detected and quantified in plasma samples of women with asymptomatic cervical infection. Further knowledge on HPV dissemination through the blood stream of women with cervical lesions would be very important in better understanding the natural history of HPV infection as well as its potential role in other distant tumors.
[Mh] MeSH terms primary: Alphapapillomavirus/genetics
Cervical Intraepithelial Neoplasia/virology
Cervix Uteri/virology
DNA, Viral/metabolism
[Mh] MeSH terms secundary: Adult
DNA, Viral/blood
Female
Humans
Middle Aged
[Pt] Publication type:JOURNAL ARTICLE
[Nm] Name of substance:0 (DNA, Viral)
[Em] Entry month:1712
[Cu] Class update date: 171226
[Lr] Last revision date:171226
[Js] Journal subset:IM
[Da] Date of entry for processing:171129
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0188592

  9 / 5382 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 28883273
[Au] Autor:Mutoh T; Takatsuki H; Mannoji K; Kawamura K; Okura N; Ohshima K
[Ad] Address:Department of Hematological Internal Medicine, Kokura Medical Center, National Hospital Organization.
[Ti] Title:Regression of uterine cervical diffuse large B-cell lymphoma transformed from mucosa-associated lymphoid tissue lymphoma subsequent to Chlamydia trachomatis eradication.
[So] Source:Rinsho Ketsueki;58(8):912-916, 2017.
[Is] ISSN:0485-1439
[Cp] Country of publication:Japan
[La] Language:jpn
[Ab] Abstract:A 37-year-old-woman was referred to our center after her uterine cervix health screening presented abnormal findings. We performed a biopsy of the uterine cervix to examine for cervical dysplasia, and diagnosed a diffuse large B-cell lymphoma transformed from mucosa-associated lymphoid tissue (MALT) lymphoma of the cervix. The patient presented with concurrent chlamydial cervicitis and received eradication therapy for Chlamydia trachomatis. Four months later, the CD20 positive abnormal lymphocyte disappeared and complete remission was achieved. MALT lymphoma is considered to correlate with infection and inflammation. Particularly, the relationship between gastric MALT lymphoma and Helicobacter pylori is well known. MALT lymphoma of the uterine cervix is rare, and its relationship with C.trachomatis infection is unknown. Further studies are warranted to investigate this association.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1709
[Cu] Class update date: 171019
[Lr] Last revision date:171019
[St] Status:In-Process
[do] DOI:10.11406/rinketsu.58.912

  10 / 5382 MEDLINE  
              first record previous record
select
to print
Photocopy

[PMID]: 28870901
[Au] Autor:Vora M; Alattia LA; Ansari J; Ong M; Cotelingam J; Coppola D; Shackelford R
[Ad] Address:Department of Pathology and Translational Pathobiology, LSU Health, Shreveport, LA, U.S.A.
[Ti] Title:Nicotinamide Phosphoribosyl Transferase a Reliable Marker of Progression in Cervical Dysplasia.
[So] Source:Anticancer Res;37(9):4821-4825, 2017 09.
[Is] ISSN:1791-7530
[Cp] Country of publication:Greece
[La] Language:eng
[Ab] Abstract:BACKGROUND/AIM: Nicotinamide phosphoribosyl transferase (Nampt) catalyses the rate-limiting step of the mammalian nicotinamide adenine dinucleotide (NAD) salvage pathway. Nampt is highly expressed in several epithelial and mesenchymal neoplasms, where is promotes cell-cycle progression ans chemotherapy resistance. To our knowledge, alterations in Nampt expression have not been examined in cervical intraepithelial neoplasia (CIN) or squamous cell carcinoma (SCC). MATERIALS AND METHODS: We performed immunohistochemical analysis for Nampt using tissue microarrays on 14 samples of benign cervical squamous epithelium and 15 CIN I, 15 CIN II, and 13 samples of CIN III. The SCCs included 5 low-grade, 67 intermediate-grade, and 81 high-grade tumors. RESULTS: Nampt levels increased with increased CIN grades were compared to benign cervical squamous epithelium. Similarly, Nampt levels increased with increasing SCC grade. CONCLUSION: Nampt expression is a reliable marker of progression in cervical dysplasia and SCC.
[Mh] MeSH terms primary: Biomarkers, Tumor/metabolism
Cytokines/metabolism
Disease Progression
Nicotinamide Phosphoribosyltransferase/metabolism
Uterine Cervical Dysplasia/enzymology
Uterine Cervical Dysplasia/pathology
[Mh] MeSH terms secundary: Cervix Uteri/pathology
Female
Humans
Immunohistochemistry
Tissue Array Analysis
[Pt] Publication type:JOURNAL ARTICLE
[Nm] Name of substance:0 (Biomarkers, Tumor); 0 (Cytokines); EC 2.4.2.12 (Nicotinamide Phosphoribosyltransferase); EC 2.4.2.12 (nicotinamide phosphoribosyltransferase, human)
[Em] Entry month:1709
[Cu] Class update date: 170918
[Lr] Last revision date:170918
[Js] Journal subset:IM
[Da] Date of entry for processing:170906
[St] Status:MEDLINE


page 1 of 539 go to page                         
   


Refine the search
  Database : MEDLINE Advanced form   

    Search in field  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information